FDA Program Cuts Loom If ‘Cures’ Bill Isn’t Fully Funded, Ostroff Warns
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s acting commissioner says agency may have to ‘stop doing something else’ in order to cover the new responsibilities envisioned in the Cures legislation.
You may also be interested in...
US FDA's Ostroff, Twice An Acting Commissioner, Retiring Next Year
A former Walmart executive will replace the deputy commissioner for foods and veterinary medicine, who spent nearly 15 months total as acting commissioner.
Califf Sets Exit At FDA, Ostroff Could Return To Acting Commissioner Post
Former acting commissioner in line for the temporary position again under FDA policy, unless incoming Trump administration designates someone else.
US FDA Might Be Temporarily Headed By Ostroff As Califf Sets His Departure
Former acting commissioner in line for the temporary position again under FDA policy, unless incoming Trump administration designates someone else.